Maxx Chatsko

Procter & Gamble will remove environmentally-unfriendly phosphates from its laundry detergents by 2016; following sustainability initiatives from Johnson & Johnson, Unilever, and Colgate-Palmolive. The projects could lead to huge benefits for the environment, consumers, and investors. Here's how.

Beginning ramp-up at a commercial scale facility marks the biggest announcement yet for Industrial biotech company Solazyme. What does it mean for the company and its investors?

After delivering gains of nearly 640% in the last decade, what should investors expect from Monsanto Company going forward?

As Americans worry about the reach of the NSA and privacy concerns, a policy enacted as part of the Energy Independence Act of 2007 under the Bush Administration will extend its reach into every American household this year. A recent poll showed that only 40% of Americans are even aware of it. Luckily, strict light bulb standards are nothing to fear. In fact, they can save you a lot of money.

Renewable Energy Group entered 2014 facing uncertainty surrounding the expiration of the blender's tax credit for biodiesel.

The media swarmed over Illumina's announcement of a system capable of sequencing a human genome for $1,000 in the near future, but when will the company and Thermo Fisher Scientific break that barrier on a routine basis?

Large-scale genome editing can create entirely new organisms, but it can also create a number of growth opportunities for your portfolio. Here's how Agilent Technologies, Intrexon, and Solazyme can keep your portfolio chugging along in 2014.

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

The biotech industry exploded higher in 2013, but these three companies promise to keep the party going in 2014.

The new 2015 Ford F-150 has shed up to 700 pounds, which significantly ups the ante for automakers racing to comply with the aggressive new CAFE standards. How much could it save you in fuel costs? And how will next-generation innovations from Ford, General Motors, and Magna International further improve upon aluminum designs?

The synthetic biology industry has erupted in recent years. The technological breakthroughs can touch numerous industries, from health care to marijuana production.

The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.

Uncle Sam relies on nuclear power for nearly one-fifth of his energy needs. You may know that companies such as Southern Company, NRG Energy, and Duke Energy own large atomic assets, but could you name the nation's top five nuclear power plants?

Industrial biotech company Solazyme is expected to start up commercial scale operations of its first two biorefineries soon. Where should investors set their expectations for the company in 2014 and what does the start-up mean for feedstock suppliers Bunge and Archer Daniels Midland?

Industrial biotech and synthetic biology company Amyris is making progress with its disruptive platform, but will need to add production capacity to be considered a true game changer. Can partners Total, Michelin, and Usina Sao Martinho step up to the plate and help build a new biorefinery?

Woody biomass to next-generation fuels producer KiOR updated investors on its operations in 2013 and goals for 2014. Should the hesitance of partners such as FedEx, Chevron, and Weyerhaeuser to provide additional funding make you think twice about an investment?

The controversial defoliant manufactured by The Dow Chemical Company and Monsanto for the U.S. Department of Defense during the Vietnam War is rumored to be making a comeback in the form of new engineered crop varieties. Are the rumblings true or just another overblown misconception from the GMO food debate?

Why the first Generation IV nuclear reactor, designed by General Electric and Hitachi, is a game-changer.

Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect the bottom line for investors?

Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors?